骨髓纤维化患者RAS基因突变的遗传特征与预后价值
该回顾性研究分析了226例骨髓纤维化(MF)患者的112基因靶向测序数据,检出RAS突变14例(6.2%),其中NRAS突变9例(4.0%)、KRAS突变8例(3.5%)。RAS突变多为亚克隆事件,与单核细胞升高、血小板减低、骨髓原始细胞升高、脾大及VHR核型等高危特征相关。NRAS突变是原发性骨髓纤维化(PMF)的独立不良预后因素。
要点
- MF患者RAS突变率6.2%,多为亚克隆事件,常与SETBP1、SRSF2、MPL共存。
- RAS突变与单核细胞升高、血小板减低、骨髓原始细胞升高、脾大及VHR核型相关。
- NRAS突变是PMF患者OS的独立不良预后因素。
核心结论
- RAS突变在MF中多为亚克隆事件,与高危临床特征相关。
- NRAS突变是PMF的独立不良预后因素。
研究设计与样本
- 回顾性分析2011年12月至2019年12月单中心226例PMF及post-PV/ET MF患者的112基因靶向测序数据。
主要发现
- 226例中检出RAS突变14例(6.2%),NRAS突变9例(4.0%),KRAS突变8例(3.5%),NRAS与KRAS共存3例(1.3%)。
- 所有NRAS突变位于第12-13号密码子,RAS突变中位VAF显著低于驱动突变。
- 伴RAS突变患者平均突变基因个数3.36个,无RAS突变组1.77个(P<0.001)。
- RAS突变与单核细胞升高(P=0.003)、血小板减低(P=0.026)、骨髓原始细胞升高(P=0.022)、脾肋缘下≥10 cm比例更高(P=0.005)相关。
- 突变组VHR核型比例18.2%(2/11),无突变组2.3%(3/133),P=0.031。
关键数值与推荐
- 单因素分析:NRAS突变者OS在全体MF及PMF队列中显著缩短(P=0.001,P=0.008)。
- 多因素分析:NRAS突变是PMF的独立不良预后因素。
临床怎么用
- 对MF患者进行RAS/NRAS突变检测有助于识别高危亚组。
- 伴NRAS突变PMF患者预后较差,可考虑更密切监测或强化治疗策略。
局限性
- 回顾性单中心研究,RAS突变样本量较小(14例)。
- VHR核型分析仅部分患者有数据(突变组11例,无突变组133例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the genetic characteristics, clinical features, and prognostic values of RAS mutations in patients with myelofibrosis (MF) . Methods: We analyzed 112-gene targeted sequencing data from 226 patients who had a diagnosis of either primary myelofibrosis (PMF) or post-polycythemia vera/post-essential thrombocythemia (post-PV MF and post-ET MF) from December 2011 to December 2019. A retrospective analysis of the genetic characteristics, clinical features, and prognosis of RAS mutations was performed. Results: Among 266 patients diagnosed PMF or post-PV/ET MF, RAS mutations were found in 14 (6.2%) cases, including 9 (4.0%) cases of NRAS mutations, 8 (3.5%) cases of KRAS mutations, and 3 (1.3%) cases of both NRAS and KRAS mutations. All of the NRAS mutations were located in codons 12 and 13. The median VAFs of RAS mutations were significantly lower than those of the driver mutations, confirming that they represent sub-clonal events that are acquired during the disease course. SETBP1, SRSF2, and MPL tended to be clustered with RAS mutations. Patients with RAS mutations had a higher number of additional oncogenic mutations (median, 3.36 vs 1.17, P<0.001) . RAS mutations had a statistically significant association with elevated monocyte cell counts (P=0.003) , lower platelet counts (P=0.026) , higher bone marrow blasts (P=0.022) , splenomegaly (P=0.005) , and very high-risk (VHR) karyotype abnormality percentage (P=0.031) . In univariate analysis, the OS of patients with NRAS mutations were significantly inferior in the entire MF and PMF cohorts (P=0.001, P=0.008) . In a multivariate model, NRAS retained an independent negative prognostic factor in PMF. Conclusion: RAS gene mutations were constantly related to elevated monocyte cell counts, lower platelet counts, higher bone marrow blasts, and VHR karyotype abnormality percentage that usually defined high-risk disease and often occurred as sub-clonal events. NRAS mutation is an independent poor prognostic factor in PMF. 目的: 分析骨髓纤维化(MF)患者RAS基因突变的分子特征及其临床特点和预后意义。 方法: 收集2011年12月至2019年12月在我中心有二代基因测序数据的226例MF患者临床资料,回顾性分析RAS基因突变特征、与临床和实验室参数之间的关系,及对总生存(OS)期的影响。 结果: 226例原发性骨髓纤维化(PMF)及真性红细胞增多症(PV)或原发性血小板增多症(ET)后骨髓纤维化(post-PV/ET MF)患者中,共14例(6.2%)检出RAS基因突变:NRAS突变9例(4.0%),KRAS突变8例(3.5%),NRAS及KRAS突变并存3例(1.3%)。所有NRAS突变均发生在第12-13号密码子。RAS基因突变多为亚克隆突变,常与SETBP1、SRSF2、MPL共同发生。伴RAS基因异常患者平均突变基因个数(3.36个)与无RAS基因异常组(1.77个)相比,差异有统计学意义(P<0.001)。RAS基因突变患者与无突变患者相比,外周血单核细胞水平升高(P=0.003),血小板水平减低(P=0.026),骨髓原始细胞比例升高(P=0.022),脾脏肋缘下≥10 cm患者比例更高(P=0.005)。突变组患者非常高危(VHR)染色体核型比例(18.2%,2/11)显著高于无突变组患者(2.3%,3/133)(P=0.031)。单因素分析中,NRAS基因突变的MF患者及PMF患者的OS时间较无突变患者显著缩短(P=0.001,P=0.008)。多因素分析显示,NRAS突变是影响OS的独立预后不良因素。 结论: RAS突变常与外周血单核细胞水平升高、血小板计数减低、骨髓原始细胞比例升高、VHR染色体核型等高危临床特征及实验室参数相关,多为发生在MF晚期的亚克隆突变。伴NRAS基因突变PMF及MF患者的OS时间显著缩短。.
引用
- Wu JY, Li B, Jia YJ, et al. [Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33445845. doi:10.3760/cma.j.issn.0253-2727.2020.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。